In a report released today, Stephen Brozak from WBB Securities maintained a Hold rating on Kadmon Holdings (NYSE: KDMN), with a price target of $2.90. The company’s shares closed yesterday at $2.89, close to its 52-week low of $2.62.
Brozak wrote:
“We are updating our coverage based on the current market capitalization of KDMN at $327 million, its updated revenue drivers, its continued clinical development path progress and the recent realization of our previous12-month price target. Our assumptions use a 114MM share count with a sum-of-the-parts model, assigning a value of $10 million for current revenue program organization, $150 for the development platform, $50MM for their stake in MGTX and $120 million for current cash. This results in a new twelve-month price target of $2.90. RISKS Indebtedness could adversely affect KDMN. Current debt is $28 million to Perceptive Credit Holdings, LP with no principal payments required until December 31, 2019. Thereafter monthly payments of $750,000 are required until principal is repaid.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 15.2% and a 47.2% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Tetraphase, and Athersys.
Currently, the analyst consensus on Kadmon Holdings is a Moderate Buy with an average price target of $13.95.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.86 and a one-year low of $2.62. Currently, Kadmon Holdings has an average volume of 714K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.
